done bilaterally for a total of 60 ml of BMA. The bone marrow was filtered, then processed in the Arteriocyte Magel-lan ® system which enables the rapid bedside processing of a "closedsystem" concentration of bone marrow aspirate and whole blood. (Arteriocyte Medical Systems, Inc., Hopkinton, MA). Figure 3a & 3b The Magellan ® was programmed to deliver 3 ml of cBMA from 60 ml of processed bone marrow. The 30 ml of whole blood was then processed in the Magellan ® to yield 3 ml of PRP, delivering a platelet concentration of 6-7X base-line, and was then added to the cBMA. The final 6 ml cBMA/PRP cocktail was mixed with a DBM graft and placed at the defect site ( Figure 3c , 3d & 4). (Note: the volume of cBMA needed is dependent on the saturation instructions for the DBM being used.) All patients under-went the Ilizarov method of external fixation [9] (Figure 5 ).
Results
After 26 months of follow-up, 35 of the 42 patients (83%) obtained solid arthrodesis as confirmed by CT scan, were stable, without infection, and pain free. Average time to fusion in healed patients was 22 weeks. (Representative patient - Figure 6 ) Of the remaining seven patients, 3 were mobile with painful non-unions that were braceable and 4 were non-mobile with non-unions requiring additional surgery, but were pain free.
Summary
It is the opinion of the author that saturating DBM graft material with a bedside processed autologous cBMA has increased fusion rates and decreased potential complications in these complex arthrodesis procedures. 
